Background: The digestion of sphingolipids (SL) is slow and is catalyzed by mucosal enzymes. Dietary SL was shown to inhibit cholesterol absorption and to lower plasma cholesterol, triglycerides (TG) and hepatic fat accumulation in animal models. Aim: A dairy formulation based on fractionation of buttermilk, which is enriched in milk polar lipids of which SL account for a large part is now available. In this study, we examined whether this formulation, when ingested with a standard breakfast, exerted a different influence on postprandial lipids than an equivalent control formulation lacking the polar milk lipids. Methods: A total of 18 healthy male volunteers aged 22-65 years ingested a high-fat (40 g) standard breakfast together with a milk-like formulation containing 975 mg of milk SL (A) or the control formulation (B). Postprandial levels of TG, total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, apolipoprotein AI (ApoAI), ApoB, glucose and insulin were measured 1 to 7 h after the meal. Results: No difference was seen between experimental and control groups in postprandial levels of TG, insulin, ApoA1 or ApoB. After 1 hour there was a trend of lower cholesterol concentrations in large TG-rich lipoproteins after formulation A. Conclusion: The SL-rich buttermilk drink may affect cholesterol concentrations in TG-rich lipoproteins, but has no effect on postprandial TG after a breakfast with butter fat as the major lipid.
Introduction
Dietary polar lipids may have beneficial health effects. Glycerophospholipids as soy lecithin lower low-density lipoprotein (LDL) and increase high-density lipoprotein (HDL), although the LDL-lowering effect is hard to differentiate from the effect of the high content of linoleic acid in this formulation (Knuiman et al., 1989; O'Brien and Andrews, 1993) . Sphingolipids (SL) are a small component in the normal diet (Vesper et al., 1999) , and studies in which SL-enriched formulations are given to humans have earlier been hard to conduct. A dairy formulation, enriched in buttermilk polar lipids, is now available. This formulation can be administered in a milk drink-like formulation containing 2-3 times the normal daily intake of dietary SL per serving.
We showed earlier that the digestion of SL is extended and catalyzed by mucosal enzymes (Nilsson and Duan, 2006) . When cholesterol was given together with sphingomyelin, an inhibitory effect on cholesterol absorption could be demonstrated in intact (Nyberg et al., 2000) as well as lymphatic duct cannulated rats (Noh and Koo, 2004 ) and mice, and in CaCO 2 cell cultures (Eckhardt et al., 2002) . In ApoE Leyden mice, a genetically modified animal model that reacts to dietary changes more like humans than like wild-type mice, SL were shown to decrease plasma cholesterol and triglyceride (TG) levels when the animals were on a high-fat and high-cholesterol diet. The effect was shown to be linked to an inhibitory effect on cholesterol and lipid absorption. In this experimental model, the SL also decreased the accumulation of fat in the liver (Duivenvoorden et al., 2006) . In vitro addition of SL inhibit the action of pancreatic lipases (Patton and Carey, 1981) . In this study, we raised the question whether a recently developed tasty milk drink formulation, enriched in milk fat globule membrane polar lipids, influenced the postprandial lipids and lipoprotein profile. These parameters are well known indicators of cardiovascular risk and can be influenced by numerous dietary factors (Lopez-Miranda et al., 2007) .
Methods
The test drink A used in this study was based on processed and enriched buttermilk and contains 4% Lacprodan PL-20 powder from Arla Foods Amba (Ingredients Division/ R&D Department, Scheelevägen 17, Lund, Sweden). This powder contains 20% (w/w) milk phospholipids originating from the serum phase of butter oil production. The test drink (A) contains 700 mg sphingomyelin, 180 mg glucoceramides and 95 mg gangliosides (mainly GD3). Total amount of SL was 975 mg in one portion of 340 ml. A placebo drink (B) was made using 5.82% skim milk powder containing 37% protein in which the phospholipids have been replaced by 2/3 of egg phospholipids isolate by Fresenius GmbH (Fresenius Biotech GmbH, München, Germany) and 1/3 butter oil. The placebo drink contains 119 mg of SL per portion. The cholesterol content was adjusted to be the same in both drinks, that is, 11 mg per 100 ml or 38 mg per serving. Based on dry weight, both formulations contained 58.5% milk protein and 6.6% lactose as major constituents. The drinks has been subjected to heat treatment at 143 1C for 6 s and poured into Tetra Brick containers under aseptic conditions. The sterility of the drink has been verified by a certified bacteriological control laboratory. Test and placebo drink was manufactured at Trenums Industries, Tingsryd, Sweden, under supervision of Arla-experts. Trenums is an approved facility for manufacturing food items. The drinks were stored in refrigerator and it is recommended to shake it a little before consumption.
A total of 20 male healthy volunteers in the age of 21-65 years, mean age of 39 years and mean BMI 24.3 were recruited through announcements on local intranet and advertisement in different work places in Lund. Exclusion criteria were abnormal fasting blood glucose levels and hyperlipidemia in addition to signs of liver or kidney disease or inflammatory activity, as indicated by raised C-reactive protein, liver tests (bilirubin, alkaline phosphatase, gammaglutamyltranspeptidase and aminotransferases) and creatinine levels. All participants gave their written informed consent before the study. The study was registered and approved by the Regional Human Ethics Committee of Lund-Malmö, Sweden.
The subjects were fed a standard breakfast containing the milk drink or the control formulation in a randomized crossover design and the wash out period between trial days was 10-14 days. The breakfast consisted of one 275 g portion of semolina pudding (8.0 g fat, 1029 KJ), 28 ml cream (10.1 g fat, 392 kJ), 20 g butter (16.2 g fat, 596 kJ), one slice of bread (0.8 g fat, 298 kJ), 17 g liver paste or 15 g cheese (4.0 g fat, 202-214 kJ) and 16 g blackberry jam (128 kJ; Table 1 ). Coffee or tea was served, without sugar, and the cream could be taken with these drinks or with the semolina pudding and blackberry jam. The breakfast, except the test drinks, thus contained 2645-2657 kJ (637-640 kcal) and 39.1 g fat of which about two thirds was milk fat. The total cholesterol intake from the breakfast is 130 mg without the milk drink.
Blood samples were taken immediately before the breakfast, when the subjects were fasting since 2200 hours the night before, and after 1, 3, 5 and 7 h. The samples were analyzed for TG, cholesterol, blood glucose, insulin, HDL and LDL cholesterol, apolipoprotein AI (ApoAI) and ApoB, liver tests, C-reactive protein, hemoglobin, white blood cell count and platelet count. Baseline concentrations of plasma lipids before each trial are shown in Table 2 . All analyses were done at the Department of Clinical Chemistry, University Hospital of Lund, Sweden using the accredited routine methods developed by Roche Diagnostics (Roche Diagnostics Limited, West Sussex, UK) (MSDS-COBAS IntegraGeneral Chemistry). In all, 2 ml EDTA-plasma was frozen for other analyses if motivated.
Participants conducted food registrations in the form of diaries over 4 days before experiments were performed and the intake was analyzed by the use of Dietist XP software with the Swedish National Food Administration database (20080306; Kost och Näringsdata, (Livsmedelsverket, Uppsala, Sweden). Dietary intakes were related to recommended Swedish dietary guidelines (SNF A, 2005). 
Statistical analysis
Significance of differences between the results obtained with the A and the B formulation were examined using paired analysis of variance multiple measures. Bonferroni's post hoc test was carried out when significant differences between diets were found. The calculation of incremental area under curve (AUC) and AUC were done using the trapezoid rule. The Student's paired t-test was used to calculate if there were any difference between cholesterol in TG-rich lipoproteins after formulations A and B after 1 hour since this was the time for the highest lipoprotein output. All statistical analyses and calculations of incremental AUC were performed with GrahpPad Prism (version 5.00, GraphPad software, San Diego, CA, USA).
Results
Characteristics of the plasma lipid levels from 18 of the 20 participants in fasting state are shown in Table 2 . One did not fulfill the study and values from one participant were excluded owing to protocol deviation. The fasting values for this subject was 7.5 mmo/l TG and 13 mIU/l insulin probably because of heavy eating and drinking after 2200 hours. The study was participant blinded and randomized with regard to the order in which formulations A and B were taken. We received registration of food intake before each trial from nine individuals, but only eight participants are included in Table 3 . We excluded the registration from the person who deviated from the protocol and presented elevated fasting TG levels mentioned above. The effects on postprandial parameters of the two lipid formulations are shown in Figure 1 . As shown in Figure 1a , the postprandial TG responses were almost identical after formulations A and B. The concentrations were highest after 1 h and then declined. After 7 h, they were slightly lower than the fasting values. In case of total cholesterol, the postprandial concentrations were slightly lower after formulation A, but the differences were small and not statistically significant (Figure 1b ). There were no statistically significant difference between the A and the B formulations in insulin and glucose levels (Figures 1c and d) . The postprandial decreases in HDL and LDL cholesterol at 1 and 3 h after the B formulation exceeded those obtained with formulation A (Figures 1 e and f) . At the later time intervals, HDL cholesterol was higher after the A than after the B formulation but the difference was, however, not significant with paired analysis of variance multiple measures. To estimate the postprandial concentrations of cholesterol in TG-rich lipoproteins, we subtracted both LDL and HDL cholesterol from total cholesterol (Figure 2a ). We observed a 30% lower incremental AUC with formulation A, but the difference was not statistically significant. At 1 hour postprandially, the time point at which the intestinal output of TG-rich lipoproteins is culminating, there was a trend (P ¼ 0.063) that cholesterol concentrations in TG-rich lipoproteins were lower after formulation A. As the intestine is a source of ApoA1 and ApoB48, we measure the postprandial concentrations of the individual proteins as well as the ratio. The ApoB/ApoA1 ratio reflects to some extent the concentration of small dense LDL (Figure 2b ). In this study, the ApoB and ApoA1 (individual concentrations not shown), or the ApoB/ApoA1 ratio did not differ postprandially between the formulations.
The ingestion of the meal took about 20 min and the measurements were performed 1 hour after the end of the meal. The incremental AUCs for the different parameters were not significantly different between formulations A and B (Table 4) .
Discussion
This paper shows that a dairy formulation containing 975 mg SL, of which 700 mg is sphingomyelin, and polar dairy glycerophospholipids as well, did not influence the postprandial TG increase from a high-fat breakfast. There was a trend that cholesterol concentrations in TG-rich lipoproteins (total cholesterol excluding HDL and LDL) were lower after formulation A. It is possible that a larger study could have presented a true difference but with present data, we do not consider this as proof of a SL-mediated inhibition of cholesterol absorption.
Earlier animal experiments demonstrated both an inhibition of cholesterol absorption with sphingomyelin (Nyberg et al., 2000; Eckhardt et al., 2002; Noh and Koo, 2004 ) and a cholesterol-and TG-lowering effect of several SL in ApoE Leyden mice fed with a cholesterol-and lipid-rich diet with 0.2-1% of the respective SL in the diet for 4 weeks (Duivenvoorden et al., 2006) . Recently, milk polar lipids were shown to reduce hepatic steatosis and hyperlipidemia in C57BL/6 mice (Wat et al., 2009) . As the reason behind the effects in rodents has not been clarified, any explanation for the lack of effect on postprandial lipids in humans must be speculative. Indirect measurements of TG fatty acid Intake the day before trial. Mean of eight subjects. Values are mean of eight subjects and 4 days intake ± s.d.
absorption in the ApoE Leyden mice suggested that 1% phytosphingosine decreased fatty acid absorption after a fat bolus dose (Duivenvoorden et al., 2006) . Such an effect might be exerted at the level of intestinal lipolysis (Patton and Carey, 1981) , via an effect of the sphingoid bases on the mucosal cells (Garmy et al., 2005) or on the postprandial fatty acid metabolism. Whatever the mechanism, it may obviously be influenced by the dose of SL as wells as the amount of fat and cholesterol given, and other dietary conditions. The dose of SL given in this study, that is 975 mg, should be in a range within which effects might be realistically expected, but which may still be insufficient. Furthermore, the effects seen in the ApoE Leyden mice may require the exposure to SL over longer time periods, whereas this study examines acute effects only. As a general feature, HDL and LDL cholesterol decreases initially after dietary lipid intake by the action of cholesterol ester transfer protein, which transfer cholesterol ester from both HDL and LDL to TG-rich lipoproteins during the postprandial phase. In this study, HDL decreased less with formulation A, and it is therefore difficult to conclude whether dietary SL causes inhibition of cholesterol absorption or influences the cholesterol ester transfer proteinmediated transfer of cholesterol ester from other lipoprotein classes. We also do not know at present whether this difference is because of the presence of SL in A or other components of milk fat globule membranes. For instance, the presence of milk polar lipids in the diet might increase the formation of polar lipid surface coat material, which is transferred to HDL as the TG-rich lipoproteins are metabolized by lipoprotein lipase. An earlier study showed that feeding soy lecithin with a TG-rich meal decreased the average size of postprandial lipoproteins and thus the amount of polar surface component per mass of TG (Beil and Grundy, 1980) . Soy phosphatidylcholine was also shown to increase the levels of HDL 2 levels (O'Brien and Andrews, , that is, the most phospholipid-rich HDL subfraction. Further studies including the size spectrum of TG-rich lipoproteins, activity of cholesterol ester transfer protein and lipid transfers after ingestion of polar milk lipids are necessary to explain the cholesterol findings in this study.
The relation between glucose, insulin action and ceramide in diabetes and obesity is important (Summers, 2006) . We have, however, neither found any differences in insulin or glucose levels in this study, and so far, nor been able to demonstrate any change in plasma SL after feeding the milk SL (unpublished).
Diet registrations revealed no significant difference between the intakes before the two occasions, indicating that no false-negative findings were caused by change in diet.
In summary, we found no immediate significant effect of milk polar lipids on postprandial plasma lipid levels. Thus, the result from this relatively small study on healthy individuals does not support our hypothesis that milk polar lipids affect our plasma lipids and lipoprotein profile. However, the formulation enriched in milk polar lipids was well tolerated and suitable for further human studies, for example, in diabetic and obese subjects with high-fasting and postprandial TG levels and low HDL, in which beneficial effects are plausible. 
